April 20, 2022 07:37 AM EDTUpdated 01:50 PM

Citing 'strategic considerations,' AbbVie breaks off Parkinson's deal with biotech partner

AbbVie, one of the first Big Pharmas to bet on alpha-synuclein as a target for Parkinson’s disease, seems to be cooling on the field. …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Cit­ing 's­trate­gic con­sid­er­a­tions,' Ab­b­Vie breaks off Parkin­son's deal with biotech part­ner